- Company
- Will Trodelvy be deliberated for reimb by DREC in August?
- by Eo, Yun-Ho Jul 11, 2024 05:47am
- The road to reimbursement for the new ADC breast cancer drug Troldelvy remains a bumpy one. The agenda remains pending for 8 months now. Gilead Sciences' triple-negative breast cancer (TNBC) drug Troldelvy, whose reimbursement request received 100,000 consents in a public petition, was not presented for deliberation to the Health Insuranc
- Company
- From obesity to brain diseases...expansion of GLP-1 agonists
- by Son, Hyung-Min Jul 11, 2024 05:46am
- The domestic pharmaceutical bio industry is looking into the possibility of developing various new drugs with GLP-1 agents. As Novo Nordisk and Lilly's GLP-1-based obesity drugs have become global blockbusters, latecomers are also avidly developing jumping in to develop the next blockbuster. Major domestic companies are conducting clinical s
- Company
- GC Biopharma ships first batch of ‘Alyglo’ to the U.S.
- by Son, Hyung-Min Jul 10, 2024 05:48am
- GC Biopharma announced on the 8th that it has completed the shipment of the first batch of its blood product ‘Alyglo’, which was approved by the U.S. Food and Drug Administration (FDA) late last year. The shipment will be delivered to specialized pharmacies through warehouses and distributors in the U.S. and is expected to be available f
- Company
- Tecentriq reapplies for reimb in early stage NSCLC
- by Eo, Yun-Ho Jul 10, 2024 05:48am
- The immuno-oncology drug Tecentriq is reattempting to expand insurance reimbursement to early-stage lung cancer. According to Dailypharm coverage, Roche Korea's PD-L1 inhibitor Tecentriq (atezolizumab) will be presented to the Health Insurance Review and Assessment Service's Cancer Disease Deliberation Committee today (July 10). The s
- Company
- With Lixiana and Enhertu, Daiichi-Sankyo’s sales growth↑
- by Hwang, Byung-woo Jul 9, 2024 06:07am
- Daiichi-Sankyo Korea has achieved continuous sales growth over the past five years with Enhertu (ingredient: trastuzumab deruxtecan) and Lixiana (ingredient: edoxaban). Last year, it recorded sales of KRW 274 billion, nearing sales of KRW 300 billion. Its operating benefit also topped its peak over the past five years. Japan-based pharmac
- Company
- Industry struggles to develop new atopic dermatitis drugs
- by Son, Hyung-Min Jul 9, 2024 05:51am
- The domestic pharmaceutical bio-industry is facing difficulties in developing new drugs for atopic dermatitis. Recently, Kangstem Biotech's stem cell therapy drug completed Phase III clinical trials, but the results fell short of expectations. JW Pharmaceutical's atopic dermatitis drug candidate failed to prove its efficacy in a Phase II clinica
- Company
- Takeda seeks top-line growth to KRW 300 billion
- by Hwang, Byung-woo Jul 9, 2024 05:51am
- Takeda Pharmaceuticals Korea achieved a double win last year, seeing improvements in sales and operating income. In particular, thanks to the growth of its anti-cancer drug portfolio, the company's sales exceeded the KRW 250 billion mark for the first time in 3 years since 2020, increasing sales growth for the second consecutive year. i
- Company
- HCV testing added to the National Health Screening Program
- by Hwang, Byung-woo Jul 8, 2024 05:46am
- The government's decision to introduce the long-discussed hepatitis C antibody testing to the national screening program is expected to have a positive impact on its treatment market. According to industry sources, the decision is encouraging as it enables the first step of identifying hepatitis C patients. However, how to link diagnosis and
- Company
- New PNH drugs introduced into AstraZeneca’s reign
- by Son, Hyung-Min Jul 8, 2024 05:45am
- Competition is in full swing in the paroxysmal nocturnal&160;hemoglobinuria (PNH) market, which is currently dominated by AstraZeneca's treatments such as Soliris and Ultomiris, with the introduction of new drugs that have new mechanisms of action soon to emerge in the market. Recently, Handok's Empaveli is nearing reimbursement in Korea, and N
- Company
- K-Bio receives FDA Orphan Drug Designations with novel drugs
- by Son, Hyung-Min Jul 8, 2024 05:45am
- In the first half of the year, Korean biopharmaceutical companies succeeded in obtaining numerous Orphan Drug Designations. Few patients have rare diseases but developing innovative new drugs can create added value and an exclusive position in the market. In the United States, if a drug is designated as an orphan drug, it is provided seven years
